Fox Chase Cancer Center Awarded More Than $25 Million Since 1993 from U.S. Department of Defense for Cancer Research
PHILADELPHIA (June 30, 2003) — Fox Chase Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute, has received more than $2 million in grant funding from the Department of Defense in 2003, bringing its 10-year grant total to more than $25 million.
The Department of Defense administers research funding via the Congressionally Directed Medical Research Programs (CDMRP). The CDMRP (http://cdmrp.army.mil) originated from a unique partnership among the public, Congress and the Department of Defense.
Fox Chase Cancer Center has received 47 awards totaling $25,962,595* from the Department of Defense since the inception of the CDMRP in 1993. Grants have been awarded to Fox Chase for research on prostate, breast and ovarian cancers, chronic myelogenous leukemia and tuberous sclerosis.
In 2000, Fox Chase behavioral researcher Suzanne Miller, PhD, was awarded a Center of Excellence award worth more than $6 million for the development of the nation's first Behavioral Center of Excellence for Breast Cancer Research.
The Behavioral Center of Excellence is the first program of its kind to comprehensively address unresolved issues relating to the impact of breast cancer on women and their families. The program will focus entirely on the psychosocial needs of women at risk of breast cancer, those undergoing treatment or palliative care, and those recovering from the disease.
Funding is awarded after a peer review of grant proposals. The process is highly competitive. Awards are given through a variety of mechanisms, including institutional training grants (to support postgraduate postdoctoral training programs in cancer research); idea development awards (to encourage innovative approaches to cancer research); concept awards (a mechanism designed to fund an innovative concept or theory); clinical translational research awards; and Center of Excellence awards.
The CDMRP began awarding grants in the 1993 fiscal year. Grassroots advocacy organizations provided much of the impetus that led Congress to appropriate $25 million for the CDMRP in 1992. This funding was intended for research on the screening and diagnosis of breast cancer among military women and dependents. In response to continuing public requests led by the National Breast Cancer Coalition, Congress appropriated an additional $210 million in FY93.
Since that time, the CDMRP has expanded to become second only to the National Cancer Institute as a source of funding for breast cancer research. After noteworthy success in managing the Breast Cancer Research Program, the CDMRP was charged with managing research programs in defense women's health, osteoporosis, neurofibromatosis, prostate cancer, ovarian cancer, tuberous sclerosis and chronic myelogenous leukemia as well as other specified areas.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.